Dr. Kathleen Jacobs

Kathleen has a background in Biotechnology and holds a PhD in Animal Sciences. She has spent over 20 years in the food and pharmaceutical sectors, before joining Rousselot’s Regulatory Affairs team in 2020.

Which aspect of your work inspires you the most?

Rousselot thinks along with its customers, which means from a regulatory perspective my job is not limited to the biomedical products we bring to the market, but also involves understanding upcoming regulation and how this will impact our customers. Our customers are developing in a wide range of innovative biomedical applications such as 3D bioprinting, organ on a chip, innovative medical devices and biologics – and together we are driving the of the future of biomedical applications.

How do you see the future of gelatin/collagen in biomedical applications?

Collagen is the most abundant protein in the body, using this highly biocompatible natural polymer to create novel biomedical solutions just makes sense. The future of gelatin and collagen as a biomaterial for biomedical applications, is being enabled by the expertise and knowledge sharing between our research team and our customers.